Telemedicine marketing built around enrolled patients and lasting value.

We start with the services the provider actually offers and the requirements of the relevant channels. The marketing explains the clinical program and patient experience rather than assuming every program can use the same campaign approach. For a national GLP-1 telehealth practice, Google Ads built after LegitScript certification produced 200+ new patients in 60 days at a $22 cost per lead.

The objective is appropriate patient enrollment and sustainable growth. We distinguish inquiries, enrollment, active subscriptions, retention, and acquisition cost so the economics are clearer. Our 2026 benchmark report found that telehealth and DTC funnels collapse lead and patient into one quiz or onboarding flow, so the meaningful number for the category is cost per acquired patient ($100 to $250), not cost per lead.

Yes. We begin with the care model, service availability, market position, and enrollment experience, then connect those foundations with the launch channels. For prescription programs we sequence compliance first: in the GLP-1 telehealth case, the LegitScript application went in at week 0 and campaigns went live in week 5, after certification, a landing page rebuild, and campaign structure.

We make the actual differences visible: clinician relationships, service process, patient support, or a specific focus. The story should give patients concrete reasons to evaluate the program rather than rely on generic claims. Against national platforms such as Hims or Ro, independent practices can offer genuine physician oversight, personalized protocols, and the kind of proactive clinical management that a platform optimized for scale can't match.

Yes. We can start with positioning and launch priorities or improve an existing program around new services, providers, or locations. An established advertising account or years of data are not prerequisites for the conversation.

With important restrictions. Meta prohibits the promotion of prescription weight loss drugs, and Google requires certification for prescription drug advertising. Compounded GLP-1 advertising has faced additional FTC scrutiny. We build GLP-1 acquisition strategies that work within these constraints, focusing on the medically supervised program and physician relationship rather than the medication itself, and using compliant landing page structures that satisfy platform policies.

Dramatically. A patient who enrolls in a $250/month hormone program is worth $3,000/year in revenue. This allows acquisition costs of $150 to $400 per enrolled patient that would be unsustainable for single-appointment practices. We build acquisition strategies with LTV in mind, willing to invest more per enrolled patient and tracking cost per enrolled subscriber rather than cost per inquiry.

Peptide therapy marketing requires careful navigation of the evolving FDA and FTC guidance on research compounds used in clinical settings. We build peptide marketing that describes the program, the physician oversight, the monitoring, the patient selection, rather than making efficacy claims for specific peptides. We stay current on regulatory developments in this space and adjust strategy as guidance evolves.

It depends on the program. Google Ads works well for programs where patients are actively searching (GLP-1, TRT, menopause, ED). Meta and Instagram work well for visual programs with strong before/after outcomes where social proof can be presented compliantly. YouTube and connected TV are increasingly effective for education-heavy programs where patients need to understand the treatment before they're ready to book. We assess channel fit for each specific program.